Literature DB >> 31518405

Pulmonary carcinosarcoma: analysis from the Surveillance, Epidemiology and End Results database.

Liangdong Sun1, Jie Dai1, Xujun Wang2, Gening Jiang1, Diego Gonzalez-Rivas1,3, Jiong Song4, Peng Zhang1.   

Abstract

OBJECTIVES: Pulmonary carcinosarcoma (PCS) is a rare neoplasm. This study explored the clinicopathological characteristics and survival outcomes of PCS.
METHODS: The Surveillance, Epidemiology and End Results (SEER) database (1988-2014) was queried for PCS. Overall survival (OS) was evaluated by multivariable Cox regression and nomograms were constructed to predict 3-year OS for PCS. Prognostic performance was evaluated using concordance index and area under the curve analysis. In M0 surgically treated patients, interaction assessments were performed using likelihood ratio tests. Subgroup analysis was performed according to patient age. The clinical features of PCSs were further compared to other non-small-cell lung cancers (NSCLCs).
RESULTS: Multivariable analysis identified age [hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.01-1.04], surgery (HR 0.53, 95% CI 0.36-0.77) and chemotherapy (HR 0.51, 95% CI 0.36-0.73) as significantly associated with OS. The nomogram had a concordance index of 0.747 and an area under the curve of 0.803. The association between age and OS was stronger in those receiving pneumonectomy (P = 0.04 for interactions) compared to those that did not (HR 5.14, 95% CI 1.64-16.07), and was associated with a poorer outcome compared to lobectomy amongst the elderly (age ≥ 70 years). Patients with PCS were more likely to receive surgical treatment and had lower lymphatic metastasis compared to adenocarcinoma, squamous cell carcinoma and large cell carcinoma (all P < 0.05).
CONCLUSIONS: PCS had unique clinical features compared to common types of NSCLCs in terms of lymphatic invasion and surgical treatment. Pneumonectomy was associated with poorer survival in elderly patients.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Age; Chemotherapy; Nomogram; Pulmonary carcinosarcoma; Surgical treatment

Mesh:

Year:  2020        PMID: 31518405     DOI: 10.1093/icvts/ivz215

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  The Prognosis of Pulmonary Sarcomatoid Carcinoma: Development and Validation of a Nomogram Based on SEER.

Authors:  Yuanyuan Xie; Zhiyong Lin; Haochun Shi; Xiang Sun; Lizhong Gu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study.

Authors:  Hao Yang; Xinqi Xiao; Tonghua Mei; Ping Zhou
Journal:  Aging Clin Exp Res       Date:  2022-03-28       Impact factor: 4.481

3.  Next-Generation Sequencing Analysis Identified Genomic Alterations in Pathological Morphologies of 3 Cases of Pulmonary Carcinosarcoma.

Authors:  Fan Li; Shan Hu; Kangle Kong; Peng Cao; Peng Han; Yu Deng; Bo Zhao
Journal:  Onco Targets Ther       Date:  2020-08-10       Impact factor: 4.147

4.  Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.

Authors:  Ziwei Liang; Enyu Zhang; Ling Duan; Nathaniel Weygant; Guangyu An; Bin Hu; Jiannan Yao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma.

Authors:  Wei-Lun Huang; Yu-Ling Huang; Chieh-Ni Kao; Yu-Wei Liu
Journal:  Thorac Cancer       Date:  2021-03-09       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.